IPP Bureau
FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
By IPP Bureau - June 03, 2026
The filing is backed by Phase III data from the lidERA Breast Cancer study
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
By IPP Bureau - June 03, 2026
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Lupin and Natco get FDA approval for Eribulin Mesylate injection
By IPP Bureau - June 03, 2026
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal
By IPP Bureau - June 03, 2026
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Cipla launches India's first sputum inflammometry lab in Mumbai
By IPP Bureau - June 03, 2026
The facility sets a new benchmark in respiratory diagnostics
Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6
By IPP Bureau - June 03, 2026
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Virohan launches Rs. 2 crore scholarship to promote health education among women
By IPP Bureau - June 03, 2026
The initiative opens pathways for female students to pursue healthcare programs across 20+ top universities and colleges in India
Granules Pharmaceuticals receives USFDA EIR for Chantilly facility
By IPP Bureau - June 03, 2026
This facility plays an important role in Granules’ global manufacturing and supply network
CORONA Remedies receives EU-GMP certification for hormone facility
By IPP Bureau - June 02, 2026
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Marksans Pharma to acquire Netherlands-based QliniQ
By IPP Bureau - June 02, 2026
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
By IPP Bureau - June 02, 2026
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes
By IPP Bureau - June 02, 2026
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
By IPP Bureau - June 02, 2026
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
CellCarta and Leica Biosystems expand push to streamline precision medicine development
By IPP Bureau - June 02, 2026
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
By IPP Bureau - June 02, 2026
The safety profile was described as manageable, though not without notable toxicities
